Volume 30, Number 5—May 2024
Research Letter
Sphingobium yanoikuyae Bacteremia, Japan
Table
Antimicrobial drug | MIC†, µg/mL | Breakpoint MIC‡, µg/mL |
---|---|---|
Piperacillin/tazobactam | <4/4 | 16/4 |
Ceftriaxone | 4 | 8 |
Ceftazidime | 2 | 8 |
Cefepime | <1 | 8 |
Aztreonam | >16 | 8 |
Imipenem | 1 | 4 |
Meropenem | 4 | 4 |
Gentamicin | <1 | 4 |
Tobramycin | <1 | 4 |
Amikacin | <4 | 16 |
Minocycline | <1 | 4 |
Ciprofloxacin | <0.25 | 1 |
Levofloxacin | <0.5 | 2 |
Trimethoprim/sulfamethoxazole | <1/19 | 2/38 |
*Drug susceptibility data according to Clinical and Laboratory Standards Institute criteria (5). MIC values for antimicrobial drugs, except ceftriaxone, were determined by using a Neg MIC NF1J panel (Beckman Coulter, https://beckmancoulter.com). The MIC value of ceftriaxone was determined by using Neg MIC EN 2J Enterobacterales and Pos MIC 1J gram-positive cocci panels (both Beckman Coulter). †MIC for the isolate from 89-year-old case-patient. ‡Breakpoints for other non-Enterobacterales susceptible strains.
References
- Takeuchi M, Hamana K, Hiraishi A. Proposal of the genus Sphingomonas sensu stricto and three new genera, Sphingobium, Novosphingobium and Sphingopyxis, on the basis of phylogenetic and chemotaxonomic analyses. Int J Syst Evol Microbiol. 2001;51:1405–17. DOIPubMedGoogle Scholar
- Yabuuchi E, Yano I, Oyaizu H, Hashimoto Y, Ezaki T, Yamamoto H. Proposals of Sphingomonas paucimobilis gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanoikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulata comb. nov., and two genospecies of the genus Sphingomonas. Microbiol Immunol. 1990;34:99–119. DOIPubMedGoogle Scholar
- Ammendolia MG, Bertuccini L, Minelli F, Meschini S, Baldassarri L. A Sphingomonas bacterium interacting with epithelial cells. Res Microbiol. 2004;155:636–46. DOIPubMedGoogle Scholar
- Guner Ozenen G, Sahbudak Bal Z, Bilen NM, Yildirim Arslan S, Aydemir S, Kurugol Z, et al. The first report of Sphingomonas yanoikuyae as a human pathogen in a child with a central nervous system infection. Pediatr Infect Dis J. 2021;40:
e524 . DOIPubMedGoogle Scholar - Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; thirty-third edition (M100-ED33). Wayne (PA): The Institute; 2023.
- Laupland KB, Paterson DL, Stewart AG, Edwards F, Harris PNA. Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality. Int J Infect Dis. 2022;119:172–7. DOIPubMedGoogle Scholar
- Ryan MP, Adley CC. Sphingomonas paucimobilis: a persistent Gram-negative nosocomial infectious organism. J Hosp Infect. 2010;75:153–7. DOIPubMedGoogle Scholar
- Mitra M, Nguyen KM, Box TW, Gilpin JS, Hamby SR, Berry TL, et al. Isolation and characterization of a novel Sphingobium yanoikuyae strain variant that uses biohazardous saturated hydrocarbons and aromatic compounds as sole carbon sources. F1000 Res. 2020;9:767. DOIPubMedGoogle Scholar
- Bui T, Preuss CV. Cephalosporins. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2024 Feb 3]. https://www.ncbi.nlm.nih.gov/books/NBK551517
1These authors contributed equally to this article.
Page created: March 01, 2024
Page updated: April 24, 2024
Page reviewed: April 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.